Over the past several months, the National Center for Advancing Translational Sciences (NCATS) has been surveying people for the presence of COVID-19 antibodies. This type of testing can provide insights into how long antibodies remain after infection and how long people may remain protected from another infection.
Given the overwhelming interest from the public in joining this study, program hubs at the University of Pittsburgh Clinical and Translation Institute (Pitt CTSI) and the University of Alabama at Birmingham (UAB) were brought in to expand enrollment capacity and diversity among the study’s participants. Thanks to the resources and infrastructure at these hubs, more than 400,000 potential participants were screened!
Between Pitt CTSI and UAB, more than 29,000 calls were made to potential participants. with Pitt CTSI responsible for over 17,000 of those calls. This led to a total enrollment of approximately 11,300 participants made up of 3,500 individuals enrolled by UAB and 5,500 enrolled by Pitt.
The National Cancer Institute will be also be supporting a study to collect further samples from these participants every 6 months, gathering more information pertaining to antibody levels after a COVID-19 infection.
Read more about this exciting study here.